Erythrocyte-Based Drug Delivery Systems

Erythrocyte‐based drug delivery systems exploit the natural properties of red blood cells—prolonged circulation, biocompatibility and immune invisibility—to transport therapeutic agents with improved pharmacokinetics and targeted action. Strategies include encapsulation of small molecules or enzymes within the cell interior, surface coupling of nanocarriers onto the erythrocyte membrane and complete cloaking of synthetic nanoparticles with erythrocyte membrane fragments. These approaches seek to harness the deformability and longevity of red blood cells to protect labile payloads from premature clearance, reduce off‐target toxicity and enable controlled release. Applications span enzyme replacement therapies, cancer chemotherapeutics, anti‐inflammatory agents and biosensing platforms. Advances in synthetic biology and nanotechnology have yielded biohybrid constructs combining living cell carriers with porous scaffolds or lipid vesicles. Emerging designs aim to integrate targeting ligands, imaging modalities and responsive release triggers to achieve organ‐specific accumulation and precision dosing. The global significance of these platforms lies in their potential to transform treatment paradigms across metabolic, cardiovascular and oncological diseases while addressing challenges of biocompatibility and manufacturing scalability.

Research from Nature Portfolio

Recent studies have demonstrated that giant unilamellar vesicles engineered by red blood cell biomimicry can withstand shear forces and immune surveillance in vivo, paving the way for large‐scale artificial cell carriers capable of prolonged drug retention and controlled release. Another seminal work has established the red blood cell‐hitchhiking technique, wherein nanoparticles adsorbed onto erythrocytes transfer efficiently to the first downstream organ after intravascular injection. This method boosts delivery by orders of magnitude to targets such as lung tissue or, when administered via carotid artery catheters, the brain, all without inducing detectable erythrocyte damage or end‐organ toxicity in multiple species.

Erythrocyte-Based Drug Delivery Systems publication trend

The graph below shows the total number of articles in erythrocyte-based drug delivery systems across all publications each year (not limited to Nature Index journals).

Technical terms

Giant unilamellar vesicles: Large, single‐membrane lipid spheres used as biomimetic carriers.

RBC‐hitchhiking: Adsorption of nanoparticles onto red blood cells to leverage their circulation and enhance targeted organ delivery.

Metal–organic framework (ZIF-8): Porous crystalline network used to protect and support enzyme cargo within biohybrid delivery systems.

Encapsulation: Encasing therapeutic agents inside intact red blood cells.

Membrane coating: Cloaking nanoparticles with erythrocyte membrane to improve biocompatibility and prolong circulation time.

References

1. Artificial cells for in vivo biomedical applications through red blood cell biomimicry. Nature Communications (2024).
2. Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications. Theranostics (2024).
3. Synthetic Biohybrids of Red Blood Cells and Cascaded‐Enzymes@ Metal–Organic Frameworks for Hyperuricemia Treatment. Advanced Science (2023).
4. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nature Communications (2018).